NEW YORK (GenomeWeb News) – Since its founding in 2005, molecular diagnostics firm Great Basin has raised $36 million in private financing, including about $9.6 million in a Series B round completed at the start of this year.

But rather than going after venture capital, the company has relied largely on three private investors for financing. When it tried to tap into the VC pipeline, the response has been singular: Not interested.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.